You are here: Home / Sites / University of Michigan / Siddiqui, Javed

Siddiqui, Javed (M.S.)

Investigator, University of Michigan, 734-764-3799

Contact Information

Email:	mailto:siddiqui@umich.edu
Fax:

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name	Biomarkers	Datasets
EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge	0	0
EDRN Pre-Validation of Multiplex Biomarker in Urine	2	0
Pre-Validation of Metabolomic Biomarkers of Prostate Cancer	0	0

Closed Protocols

Protocol Name	Biomarkers	Datasets
EDRN-WHI Pre-Clinical Colon Ca Specimens	0	9

Publications

Publication Name	PubMed ID	Journal
Humoral response profiling reveals pathways to prostate cancer progression.	18077443	Mol. Cell Proteomics
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.	18245462	Cancer Res.
Whole transcriptome amplification for gene expression profiling and development of molecular archives.	16611408	Neoplasia
Molecular markers of prostate cancer.	17138135	Urol. Oncol.
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.	28344039	Cancer Cell
Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer.	27926866	Cell Rep
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.	17409457	Cancer Res.
Characterization of KRAS rearrangements in metastatic prostate cancer.	22140652	Cancer Discov
TACO produces robust multisample transcriptome assemblies from RNA-seq.	27869815	Nat. Methods
Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.	29245011	Cell
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.	28292441	Cancer Cell
Integrative molecular concept modeling of prostate cancer progression.	17173048	Nat. Genet.
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.	17059688	Neoplasia
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.	16951139	Cancer Res.
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.	15173267	J. Natl. Cancer Inst.
Classification and selection of biomarkers in genomic data using LASSO.	16046820	J. Biomed. Biotechnol.
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.	27566105	Neoplasia
Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.	16678056	Urol. Oncol.
Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.	26280815	Cancer
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.	16286247	Cancer Cell
Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.	27159573	Prostate
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.	16585160	Cancer Res.
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.	17237811	Oncogene
Therapeutic targeting of SPINK1-positive prostate cancer.	21368222	Sci Transl Med
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.	16254181	Science
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.	17401460	Neoplasia
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.	22496589	Proc. Natl. Acad. Sci. U.S.A.
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.	22252602	Mol. Cancer Ther.
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.	21804560	Nat. Biotechnol.
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.	21724842	Genome Res.
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.	21575865	Cancer Cell
TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.	21676887	Cancer Res.
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.	22131877	Neoplasia
Personalized oncology through integrative high-throughput sequencing: a pilot study.	22133722	Sci Transl Med
Coordinated regulation of polycomb group complexes through microRNAs in cancer.	21840484	Cancer Cell
The emergence of lncRNAs in cancer biology.	22096659	Cancer Discov
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.	21813756	Sci Transl Med
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.	22101766	Nat. Med.
Systematic, evidence-based discovery of biomarkers at the NCI.	22868876	Clin. Exp. Metastasis
Autoantibody signatures in prostate cancer.	16177248	N. Engl. J. Med.
Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer.	22952423	Neoplasia
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.	17334343	Mod. Pathol.
Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data.	22497771	Genomics
Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.	22849743	Arch. Pathol. Lab. Med.
The mutational landscape of lethal castration-resistant prostate cancer.	22722839	Nature
SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing.	22787087	Cancer Discov
Expressed pseudogenes in the transcriptional landscape of human cancers.	22726445	Cell
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.	22553170	J. Pathol.
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.	22610119	Nat. Genet.
Integrating biomedical knowledge to model pathways of prostate cancer progression.	17495538	Cell Cycle
Role of the TMPRSS2-ERG gene fusion in prostate cancer.	18283340	Neoplasia
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.	17356713	Neoplasia
Antibody-based detection of ERG rearrangement-positive prostate cancer.	20651988	Neoplasia
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.	20622896	Oncogene
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.	20526349	Nat. Med.
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.	18483239	Cancer Res.
Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.	23348902	Mod. Pathol.
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.	23233736	Cancer Res.
New strategies in prostate cancer: translating genomics into the clinic.	23248095	Clin. Cancer Res.
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.	23086769	Am. J. Clin. Pathol.
Epigenomic alterations in localized and advanced prostate cancer.	23555183	Neoplasia
The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells.	23118229	J. Biol. Chem.
Role of transcriptional corepressor CtBP1 in prostate cancer progression.	23097625	Neoplasia
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.	23358695	Neoplasia
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.	23159737	Mol. Cell
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.	23313952	Nat. Genet.
Integrative analysis of genomic aberrations associated with prostate cancer progression.	17804737	Cancer Res.
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.	18172298	Cancer Res.
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.	17671502	Nature
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.	17996646	Cancer Cell
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.	18006806	Cancer Res.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Addresses

To update addresses, please visit the Data Management and Coordinating Center.